Eli Lilly has shared phase 1 data on an antibody-drug conjugate (ADC) in platinum-sensitive ovarian cancer (PSOC), shedding ...

Gilead has struck a deal to acquire PepStar Therapeutics’ oral IL-23 receptor inhibitor program for $1.275 billion, ...

Boehringer Ingelheim has shared data on its DLL3xCD3 T-cell engager, providing pointers to the prospects of a would-be rival ...

Takeda has lifted the lid on the phase 3 win for its next-generation claudin18.2 drug, with the antibody-drug conjugate (ADC) ...

Bolt Biotherapeutics is acquiring Prana Therapies in a stock-for-stock reverse merger aimed at advancing Prana’s pipeline of ...

| Pathos AI has closed a $237 million series E round led by pharma giant Bristol Myers Squibb on the same day that the two ...

Roche is paying Zymeworks $55 million upfront for ZW209, bagging global rights to a trispecific designed to improve on the ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...

Despite the sweeping scope of the ban covering various types of drug molecules, biopharma business development teams can ...

Merck & Co. and Moderna have shared highly anticipated phase 3 data on their cancer vaccine, revealing a primary endpoint hit ...

Roche’s CEO has insisted to Fierce that the company’s view on its $1.5 billion Poseida buyout has “absolutely not” changed, ...

Celltrion has licensed a preclinical antibody aimed at autoimmune conditions from Maryland-based biotech Kaigene in a deal ...